COVID-19 or Flu?
Get the answers with Flowflex PLUS
The Flowflex® PLUS COVID-19 and Flu A/B Home Test is all you need to determine your family’s COVID-19/Flu status.
Symptoms may be similar, treatments for complications differ
- 3-in-1 test for COVID-19, Flu A, and Flu B
- Easy-to-use nasal swab test
- Can be used to test children as young as 2 years old
- Results in 15 minutes
- No need to send off to a lab to obtain results
- Medical-grade technology used in doctor’s offices
- Compact packaging for “On-The-Go” testing
Test Procedure Overview
Resources
Quick Reference Instructions (English)
Quick Reference Instructions (Spanish)
Fact Sheet for Healthcare Professionals
Healthcare Provider Package Insert
Quick Instruction Card (English)
Quick Instruction Card (Spanish)
Frequently Asked Questions
Looking for a Distributor?
Need Support?
News
Flowflex® Plus COVID-19 and Flu A/B Home Test Receives FDA EUA
SAN DIEGO, CA., July 29, 2024 – ACON Laboratories, Inc., a leading global medical device manufacturer for 25 years, announced today that its Flowflex® Plus COVID-19 and Flu A/B Home Test has been authorized for emergency use by the U.S. Food and Drug Administration....
Headquartered in San Diego, California, ACON Laboratories makes point-of-care medical diagnostics accessible to people around the world. ACON provides rapid diagnostics and healthcare products based on a philosophy of high quality at affordable prices.
- In the USA, this product has not been FDA cleared or approved, but has been authorized by FDA under an Emergency Use Authorization.
- This product has been authorized only for the detection of proteins from SARSCoV-2, influenza A and influenza B, not for any other viruses or pathogens.
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
For more information on EUAs please visit: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
For the most up to date information on COVID-19, please visit: www.cdc.gov/COVID19